BRIACELL THERAPEUTICS CORP. Research and Development Expense
BRIACELL THERAPEUTICS CORP. (BCTX) reported Research and Development Expense of $5.97 million for the 3-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. research and development expense for the quarter ending 2026-04-30 was $5.97M, a 24.04% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. research and development expense for the quarter ending 2026-01-31 was $6.05M, a 6.49% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. research and development expense for the quarter ending 2025-10-31 was $6.68M, a 82.35% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. research and development expense for the quarter ending 2025-07-31 was $7.11M, a 61.40% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. research and development expense for fiscal 2025 was $21.27M, a 21.74% decline from fiscal 2024.
- BRIACELL THERAPEUTICS CORP. research and development expense for fiscal 2024 was $27.18M, a 77.21% increase from fiscal 2023.
- BRIACELL THERAPEUTICS CORP. research and development expense for fiscal 2023 was $15.34M, a 91.19% increase from fiscal 2022.
- BRIACELL THERAPEUTICS CORP. research and development expense for fiscal 2022 was $8.02M, a 296.93% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-04-30 | $5.97M 10-Q · filed 2026-06-09 | $12.02M derived: sum of 2 quarters · filed 2026-06-09 | $18.70M 10-Q · filed 2026-06-09 | $25.81M derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | $6.05M 10-Q · filed 2026-03-10 | $12.74M 10-Q · filed 2026-03-10 | $19.85M derived: sum of 3 quarters · filed 2026-03-10 | $24.66M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | $6.68M 10-Q · filed 2025-12-11 | $13.79M derived: sum of 2 quarters · filed 2025-12-11 | $18.60M derived: sum of 3 quarters · filed 2026-06-09 | $24.29M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | $7.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $11.92M derived: sum of 2 quarters · filed 2026-06-09 | $17.61M derived: sum of 3 quarters · filed 2026-06-09 | $21.27M 10-K · filed 2025-10-16 |
| 2025-04-30 | $4.81M 10-Q · filed 2026-06-09 | $10.49M derived: sum of 2 quarters · filed 2026-06-09 | $14.16M 10-Q · filed 2026-06-09 | $18.57M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-01-31 | $5.68M 10-Q · filed 2026-03-10 | $9.35M 10-Q · filed 2026-03-10 | $13.76M derived: sum of 3 quarters · filed 2026-03-10 | $21.41M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | $3.67M 10-Q · filed 2025-12-11 | $8.07M derived: sum of 2 quarters · filed 2025-12-11 | $15.73M derived: sum of 3 quarters · filed 2025-12-11 | $23.99M derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $12.06M derived: sum of 2 quarters · filed 2025-10-16 | $20.32M derived: sum of 3 quarters · filed 2025-10-16 | $27.18M 10-K · filed 2025-10-16 |
| 2024-04-30 | $7.66M 10-Q · filed 2025-06-16 | $15.92M derived: sum of 2 quarters · filed 2025-06-16 | $22.77M 10-Q · filed 2025-06-16 | $27.94M derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | $8.26M 10-Q · filed 2025-03-12 | $15.11M 10-Q · filed 2025-03-12 | $20.28M derived: sum of 3 quarters · filed 2025-03-12 | $24.14M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | $6.86M 10-Q · filed 2024-12-16 | $12.02M derived: sum of 2 quarters · filed 2024-12-16 | $15.89M derived: sum of 3 quarters · filed 2024-12-16 | $18.94M derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | $9.03M derived: sum of 2 quarters · filed 2024-10-29 | $12.08M derived: sum of 3 quarters · filed 2024-10-29 | $15.34M 10-K · filed 2024-10-29 |
| 2023-04-30 | $3.86M 10-Q · filed 2024-06-14 | $6.91M derived: sum of 2 quarters · filed 2024-06-14 | $10.17M 10-Q · filed 2024-06-14 | $13.34M derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-01-31 | $3.05M 10-Q · filed 2024-03-18 | $6.31M 10-Q · filed 2024-03-18 | $9.48M derived: sum of 3 quarters · filed 2024-03-18 | $11.75M derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | $3.26M 10-Q · filed 2023-12-14 | $6.42M derived: sum of 2 quarters · filed 2023-12-14 | $8.69M derived: sum of 3 quarters · filed 2023-12-14 | $10.40M derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-07-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-25 | $5.44M derived: sum of 2 quarters · filed 2023-10-25 | $7.15M derived: sum of 3 quarters · filed 2023-10-25 | $8.02M 10-K · filed 2023-10-25 |
| 2022-04-30 | $2.27M 10-Q · filed 2023-06-14 | $3.98M derived: sum of 2 quarters · filed 2023-06-14 | $4.85M 10-Q · filed 2023-06-14 | |
| 2022-01-31 | $1.71M 10-Q · filed 2023-03-16 | $2.58M 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | $875.64K 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | $2.02M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |